Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction (ERUPTION)
A Randomized, Parallel-controlled, Multi-center Study of the Effects of Intracoronary Recombinant HUman Prourokinase or TIrofiban on the Coronary Flow During Primary PCI for the Acute Myocardial InfartiON
Sponsor: Fudan University
Listed as NCT02131220, this PHASE4 trial focuses on Myocardial Infarction and Percutaneous Coronary Intervention and remains completed. Sponsored by Fudan University, it has been updated 7 times since 2015, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE4
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fudan University
For direct contact, visit the study record on ClinicalTrials.gov .